dromlakhani Daily vs intermittent vitamin D dosing in adults over 50
STEP 1 — Gather Information
Collect patient age, confirmation of an indication for vitamin D supplementation (e.g., osteoporosis, known deficiency, malabsorption, chronic kidney disease, etc.), and verify the patient is not pregnant (if applicable). Record these data.
STEP 2 — Rule In / Rule Out
If the patient is aged 50 years or older AND has an indication for vitamin D supplementation, proceed to Step 3; otherwise, do not apply this recommendation and consider age‑specific dosing per other guidelines.
STEP 3 — Classify or Stratify
Assess for risk factors that increase adverse event potential with intermittent high‑dose vitamin D (history of hypercalcemia, nephrolithiasis, renal impairment, or medications that accelerate vitamin D catabolism). If any risk factor is present, classify as high risk; otherwise, classify as standard risk.
STEP 4 — Decide
Recommend daily lower‑dose vitamin D (e.g., 600–800 IU per day from fortified foods, supplements, or a combination) and counsel against intermittent high‑dose regimens (e.g., 50 000 IU weekly or monthly). In patients classified as high risk, emphasize avoidance of intermittent dosing due to increased safety concerns.
Clinical Guardrails / Mimics / Pitfalls
Do not use intermittent high‑dose vitamin D (e.g., 50 000 IU weekly or monthly) in adults ≥50 y with an indication for vitamin D; do not rely on routine 25(OH)D testing to guide dosing in this population; do not exceed the tolerable upper intake level (4000 IU/day) without monitoring for hypercalcemia; do not apply this recommendation to pregnant individuals without obstetric guidance.
Concrete Clinical Example
A 62‑year‑old postmenopausal woman with osteoporosis initiates vitamin D supplementation. She is >50 y, has an indication (osteoporosis), and has no history of kidney stones or hypercalcemia. Prescribe vitamin D 800 IU daily and advise against monthly 50 000 IU doses.
Source: Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2024, DOI: 10.1210/clinem/dgae290